Livzon Pharmaceutical Group Inc. (HKG: 1513), a leading Chinese pharmaceutical company, has announced that its drug candidate JP-1366 has received clearance from the Center for Drug Evaluation (CDE) to proceed with clinical studies for reflux esophagitis. JP-1366, also known as zastaprazan, is a potassium-competitive acid-blocking (P-CAB) class drug originally developed by South Korean firm Onconic Therapeutics and is already under marketing review in South Korea.
The drug boasts advantages such as a rapid onset of action, effective acid inhibition, enduring efficacy, and a favorable safety profile with fewer adverse reactions. This clearance by the CDE is a significant step forward for Livzon Pharmaceutical Group as it expands its pipeline in gastroenterology.
In March 2023, Livzon Pharma entered into a licensing agreement with Onconic, securing exclusive rights to develop, license, manufacture, and commercialize JP-1366 in Greater China, which includes the Chinese mainland, Hong Kong, Macau, and Taiwan. This strategic partnership highlights Livzon’s commitment to bringing innovative therapies to patients in need.
The clinical study clearance for JP-1366 in reflux esophagitis underscores Livzon Pharmaceutical Group’s ongoing efforts to expand its product portfolio and enhance its presence in the therapeutic market.- Flcube.com
